To be a Medicare Agent's source of information on topics affecting the agent and their business, and most importantly, their clientele, is the intention of this site. Sourced from various means rooted in the health insurance industry - insurance carriers, governmental agencies, and industry news agencies, this is aimed as a resource of varying viewpoints to spark critical thought and discussion. We welcome your contributions.
Monday, August 12, 2019
CMS last week finalized its decision to cover...
...CAR-T cell treatments, as well as all services related to
administration of the costly therapy. Available CAR-T therapies have been slow
to pick up coverage due to their high list prices, with Gilead's Yescarta
priced at $373,000 and Novartis' Kymriah at $475,000. CMS currently facilitates
coverage for 33,301,406 people through Medicare fee-for-service.
No comments:
Post a Comment